In conclusion, this study demonstrated that the predominant mechanism of ZIKV-induced AD pathologies is PERK-eIF2α regulating the AD-associated factors, including GSK3 and BACE, and that targeting PERK activation by inhibitors has potential therapeutic implications in AD pathologies. The gene discussed is EIF2A; the disease is Alzheimer disease.